Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Study of Avapritinib (BLU-285) in Patients with Indolent Systemic Mastocytosis (ISM) or Smoldering Systemic Mastocytosis (SSM)
Sponsor:Blueprint Medicines Corporation
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS1849
U.S. Government ID:NCT03731260
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information:

This research study is a 3-part, randomized, double-blind study designed to learn more about the safety and effectiveness of an experimental drug called avapritinib (formerly called BLU-285), when given to individuals who have been diagnosed with Indolent Systemic Mastocytosis (ISM) or Smoldering Systemic Mastocytosis (SSM). Experimental means it is not yet known if the drug helps patients, and it is not available for sale. Randomized means that each patient has a random chance (like the flip of a coin) of being assigned to receive one of the treatments being tested during the study, and double-blind means that neither you nor the study doctor will know which one you are taking. Avapritinib is an experimental drug being developed by Blueprint Medicines Corporation to treat all forms of Systemic Mastocytosis (SM). It is an oral drug that is taken once a day continuously in 28-day cycles.

Do You Qualify?
Are you 18 years of age or older?YesNo
Do you have systemic mastocytosis with indolent systemic mastocytosis or smoldering systemic mastocytosis subtype?YesNo
Have you ever received avapritinib before?YesNo
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder

Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Phone: 212-342-5162